FDA pilot lets regulators monitor trial data in real time, speeding approvals

Faster drug approvals could get experimental treatments to patients sooner, but the Food and Drug Administration’s new real-time monitoring pilot also raises a harder question: whether regulators can absorb raw trial data earlier, and more often, without losing the scrutiny that protects safety and trial integrity.

The agency said on April 28 that it had launched two proof-of-concept real-time clinical trials and opened a request for information for a broader pilot that is expected to begin in summer 2026. The first studies are AstraZeneca’s Phase 2 TRAVERSE trial in treatment-naïve mantle cell lymphoma, which includes The University of Texas MD Anderson Cancer Center and the University of Pennsylvania, and Amgen’s Phase 1b STREAM-SCLC trial in limited-stage small cell lung carcinoma, with final site selection still underway. The FDA said it had already received and validated safety signals from AstraZeneca’s trial through Paradigm Health, an early sign that the technical model can work.

FDA Commissioner Marty Makary has argued that the traditional system leaves key data signals sitting outside the agency for years, and that about 45% of the time from Phase 1 to final submission is spent without an active trial in progress. The agency says that lag is especially costly in early-stage studies, where patient numbers are small, uncertainty is high and sponsor decision-making can be slow. By letting regulators see Phase 1 data without waiting for companies to finish their own analysis and documentation, the FDA is trying to cut what Makary has called dead time in drug development.

The policy shift fits into a broader modernization push. The FDA has already used faster-review models in oncology through its Real-Time Oncology Review program, which allows earlier submission of topline efficacy and safety results before a complete application is filed. It has also promoted decentralized trials with remote data collection, electronic consent, virtual visits and local lab or imaging assessments. On the technology side, the agency completed a generative AI pilot for scientific reviewers and later moved to deploy AI capabilities across the agency, while drugmakers such as Johnson & Johnson have used artificial intelligence to compress document-preparation work from hundreds of hours to about 15 minutes.

The gains could be substantial if the pilot shortens development cycles and helps the FDA spot safety problems earlier. But the tradeoffs are just as large. Real-time access means more responsibility for data security, consistency and staff workload, especially if raw trial information starts arriving before sponsors have finished cleaning and analyzing it. The FDA is now asking for input on pilot design, implementation, evaluation metrics and success criteria, a sign that the agency wants to modernize review without giving up the safeguards that define it.